Journal article
Delayed patchy choroidal filling in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)
American journal of ophthalmology, Vol.158(3), pp.525-531.e2
09/2014
DOI: 10.1016/j.ajo.2014.06.004
PMCID: PMC4458330
PMID: 24949820
Abstract
To determine the relationship between delayed patchy choroidal filling and morphologic and functional outcomes among eyes treated with ranibizumab or bevacizumab. Cohort study. Comparison of Age-related Macular Degeneration Treatment Trials participants were assigned randomly to ranibizumab or bevacizumab on a monthly or as-needed schedule. Presence of delayed patchy choroidal filling and morphologic and functional outcomes were evaluated among eyes with gradable fluorescein angiography at baseline (n = 973) and at 1 year (n = 860) eyes. Delayed filling was present in 75 (7.7%) of 973 eyes at baseline. Eyes with incident delayed filling at 1 year (23 [2.9%] of 798) showed a mean decrease of 1.7 letters in visual acuity, whereas eyes without incident delayed filling had a mean improvement of 8.1 letters (difference [Δ], -9.8; 95% confidence interval [CI] , -15.8 to -3.9; P < .01). Eyes with incident delayed filling had a larger increase in mean total lesion area of choroidal neovascularization (3.00 mm(2)) than eyes without incident delayed filling (0.56 mm(2); Δ , 2.4; 95% CI, 0.4 to 4.4; P = .02). The proportion with incident delayed filling at 1 year was similar among eyes treated with ranibizumab (10 [2.4%] of 413) or bevacizumab (13 [3.3%] of 385; P = .53) and among eyes treated monthly (12 [3.1%] of 388) or as needed (11 [2.7%] of 410; P = .83). Delayed patchy choroidal filling was uncommon at baseline. Although only a small percentage of eyes demonstrated delayed filling during the first year of anti-vascular endothelial growth factor treatment, these eyes had worse visual acuity and a larger increase in total lesion area of choroidal neovascularization.
Details
- Title: Subtitle
- Delayed patchy choroidal filling in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)
- Creators
- Dina Y Gewaily - Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: dina.gewaily@gmail.comJuan E Grunwald - Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PennsylvaniaMaxwell Pistilli - Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PennsylvaniaGui-Shuang Ying - Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PennsylvaniaMaureen G Maguire - Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PennsylvaniaEbenezer Daniel - Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PennsylvaniaCandace P Ostroff - Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PennsylvaniaStuart L Fine - Department of Ophthalmology, University of Colorado, Aurora, ColoradoCATT Research Group
- Resource Type
- Journal article
- Publication Details
- American journal of ophthalmology, Vol.158(3), pp.525-531.e2
- DOI
- 10.1016/j.ajo.2014.06.004
- PMID
- 24949820
- PMCID
- PMC4458330
- NLM abbreviation
- Am J Ophthalmol
- ISSN
- 1879-1891
- eISSN
- 1879-1891
- Publisher
- United States
- Grant note
- U10 EY017828 / NEI NIH HHS U10 EY017826 / NEI NIH HHS U10 EY017825 / NEI NIH HHS U10 EY017823 / NEI NIH HHS
- Language
- English
- Date published
- 09/2014
- Academic Unit
- Ophthalmology and Visual Sciences
- Record Identifier
- 9983979959302771
Metrics
25 Record Views